Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialZobair M. Younossi, Victor Ankoma‐Sey, Vlad Ratziu et al.|The Lancet|2019Cited by 1.2k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis WorseningVlad Ratziu, Velimir A. Luketic, Juan F. Gallegos‐Orozco et al.|Gastroenterology|2016Cited by 1k
Guidelines on the management of ascites in cirrhosisGuruprasad P. Aithal, Sumita Verma|Gut|2020Cited by 661
A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosisScott L. Friedman, Éric Lefebvre, Vlad Ratziu et al.|Hepatology|2017Cited by 657
Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline – Updated January 2017Jean‐Marc Dumonceau, Marcin Polkowski, Roald Flesland Havre et al.|Endoscopy|2017Cited by 346